Capital Asset Pricing Model (CAPM)
Capital asset pricing model (CAPM) indicates what should be the expected or required rate of return on risky assets like Vertex Pharmaceuticals Inc. common stock.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Current Ratio since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Rates of Return
Vertex Pharmaceuticals Inc., monthly rates of return
| Vertex Pharmaceuticals Inc. (VRTX) | Standard & Poor’s 500 (S&P 500) | |||||
|---|---|---|---|---|---|---|
| t | Date | PriceVRTX,t1 | DividendVRTX,t1 | RVRTX,t2 | PriceS&P 500,t | RS&P 500,t3 |
| Jan 31, 2019 | ||||||
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Average (R): | ||||||
| Standard deviation: | ||||||
| Vertex Pharmaceuticals Inc. (VRTX) | Standard & Poor’s 500 (S&P 500) | |||||
|---|---|---|---|---|---|---|
| t | Date | PriceVRTX,t1 | DividendVRTX,t1 | RVRTX,t2 | PriceS&P 500,t | RS&P 500,t3 |
| Jan 31, 2019 | ||||||
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| 4. | May 31, 2019 | |||||
| 5. | Jun 30, 2019 | |||||
| 6. | Jul 31, 2019 | |||||
| 7. | Aug 31, 2019 | |||||
| 8. | Sep 30, 2019 | |||||
| 9. | Oct 31, 2019 | |||||
| 10. | Nov 30, 2019 | |||||
| 11. | Dec 31, 2019 | |||||
| 12. | Jan 31, 2020 | |||||
| 13. | Feb 29, 2020 | |||||
| 14. | Mar 31, 2020 | |||||
| 15. | Apr 30, 2020 | |||||
| 16. | May 31, 2020 | |||||
| 17. | Jun 30, 2020 | |||||
| 18. | Jul 31, 2020 | |||||
| 19. | Aug 31, 2020 | |||||
| 20. | Sep 30, 2020 | |||||
| 21. | Oct 31, 2020 | |||||
| 22. | Nov 30, 2020 | |||||
| 23. | Dec 31, 2020 | |||||
| 24. | Jan 31, 2021 | |||||
| 25. | Feb 28, 2021 | |||||
| 26. | Mar 31, 2021 | |||||
| 27. | Apr 30, 2021 | |||||
| 28. | May 31, 2021 | |||||
| 29. | Jun 30, 2021 | |||||
| 30. | Jul 31, 2021 | |||||
| 31. | Aug 31, 2021 | |||||
| 32. | Sep 30, 2021 | |||||
| 33. | Oct 31, 2021 | |||||
| 34. | Nov 30, 2021 | |||||
| 35. | Dec 31, 2021 | |||||
| 36. | Jan 31, 2022 | |||||
| 37. | Feb 28, 2022 | |||||
| 38. | Mar 31, 2022 | |||||
| 39. | Apr 30, 2022 | |||||
| 40. | May 31, 2022 | |||||
| 41. | Jun 30, 2022 | |||||
| 42. | Jul 31, 2022 | |||||
| 43. | Aug 31, 2022 | |||||
| 44. | Sep 30, 2022 | |||||
| 45. | Oct 31, 2022 | |||||
| 46. | Nov 30, 2022 | |||||
| 47. | Dec 31, 2022 | |||||
| 48. | Jan 31, 2023 | |||||
| 49. | Feb 28, 2023 | |||||
| 50. | Mar 31, 2023 | |||||
| 51. | Apr 30, 2023 | |||||
| 52. | May 31, 2023 | |||||
| 53. | Jun 30, 2023 | |||||
| 54. | Jul 31, 2023 | |||||
| 55. | Aug 31, 2023 | |||||
| 56. | Sep 30, 2023 | |||||
| 57. | Oct 31, 2023 | |||||
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Average (R): | ||||||
| Standard deviation: | ||||||
Show all
1 Data in US$ per share of common stock, adjusted for splits and stock dividends.
2 Rate of return on common stock of VRTX during period t
3 Rate of return on S&P 500 (the market portfolio proxy) during period t
Variance and Covariance
Vertex Pharmaceuticals Inc., calculation of variance and covariance of returns
| t | Date | RVRTX,t | RS&P 500,t | (RVRTX,t–RVRTX)2 | (RS&P 500,t–RS&P 500)2 | (RVRTX,t–RVRTX)×(RS&P 500,t–RS&P 500) |
|---|---|---|---|---|---|---|
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Total (Σ): | ||||||
| t | Date | RVRTX,t | RS&P 500,t | (RVRTX,t–RVRTX)2 | (RS&P 500,t–RS&P 500)2 | (RVRTX,t–RVRTX)×(RS&P 500,t–RS&P 500) |
|---|---|---|---|---|---|---|
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| 4. | May 31, 2019 | |||||
| 5. | Jun 30, 2019 | |||||
| 6. | Jul 31, 2019 | |||||
| 7. | Aug 31, 2019 | |||||
| 8. | Sep 30, 2019 | |||||
| 9. | Oct 31, 2019 | |||||
| 10. | Nov 30, 2019 | |||||
| 11. | Dec 31, 2019 | |||||
| 12. | Jan 31, 2020 | |||||
| 13. | Feb 29, 2020 | |||||
| 14. | Mar 31, 2020 | |||||
| 15. | Apr 30, 2020 | |||||
| 16. | May 31, 2020 | |||||
| 17. | Jun 30, 2020 | |||||
| 18. | Jul 31, 2020 | |||||
| 19. | Aug 31, 2020 | |||||
| 20. | Sep 30, 2020 | |||||
| 21. | Oct 31, 2020 | |||||
| 22. | Nov 30, 2020 | |||||
| 23. | Dec 31, 2020 | |||||
| 24. | Jan 31, 2021 | |||||
| 25. | Feb 28, 2021 | |||||
| 26. | Mar 31, 2021 | |||||
| 27. | Apr 30, 2021 | |||||
| 28. | May 31, 2021 | |||||
| 29. | Jun 30, 2021 | |||||
| 30. | Jul 31, 2021 | |||||
| 31. | Aug 31, 2021 | |||||
| 32. | Sep 30, 2021 | |||||
| 33. | Oct 31, 2021 | |||||
| 34. | Nov 30, 2021 | |||||
| 35. | Dec 31, 2021 | |||||
| 36. | Jan 31, 2022 | |||||
| 37. | Feb 28, 2022 | |||||
| 38. | Mar 31, 2022 | |||||
| 39. | Apr 30, 2022 | |||||
| 40. | May 31, 2022 | |||||
| 41. | Jun 30, 2022 | |||||
| 42. | Jul 31, 2022 | |||||
| 43. | Aug 31, 2022 | |||||
| 44. | Sep 30, 2022 | |||||
| 45. | Oct 31, 2022 | |||||
| 46. | Nov 30, 2022 | |||||
| 47. | Dec 31, 2022 | |||||
| 48. | Jan 31, 2023 | |||||
| 49. | Feb 28, 2023 | |||||
| 50. | Mar 31, 2023 | |||||
| 51. | Apr 30, 2023 | |||||
| 52. | May 31, 2023 | |||||
| 53. | Jun 30, 2023 | |||||
| 54. | Jul 31, 2023 | |||||
| 55. | Aug 31, 2023 | |||||
| 56. | Sep 30, 2023 | |||||
| 57. | Oct 31, 2023 | |||||
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Total (Σ): | ||||||
Show all
VarianceVRTX = Σ(RVRTX,t–RVRTX)2 ÷ (59 – 1)
= ÷ (59 – 1)
=
VarianceS&P 500 = Σ(RS&P 500,t–RS&P 500)2 ÷ (59 – 1)
= ÷ (59 – 1)
=
CovarianceVRTX, S&P 500 = Σ(RVRTX,t–RVRTX)×(RS&P 500,t–RS&P 500) ÷ (59 – 1)
= ÷ (59 – 1)
=
Systematic Risk (β) Estimation
| VarianceVRTX | |
| VarianceS&P 500 | |
| CovarianceVRTX, S&P 500 | |
| Correlation coefficientVRTX, S&P 5001 | |
| βVRTX2 | |
| αVRTX3 |
Calculations
1 Correlation coefficientVRTX, S&P 500
= CovarianceVRTX, S&P 500 ÷ (Standard deviationVRTX × Standard deviationS&P 500)
= ÷ ( × )
=
2 βVRTX
= CovarianceVRTX, S&P 500 ÷ VarianceS&P 500
= ÷
=
3 αVRTX
= AverageVRTX – βVRTX × AverageS&P 500
= – ×
=
Expected Rate of Return
| Assumptions | ||
| Rate of return on LT Treasury Composite1 | RF | |
| Expected rate of return on market portfolio2 | E(RM) | |
| Systematic risk (β) of Vertex Pharmaceuticals Inc. common stock | βVRTX | |
| Expected rate of return on Vertex Pharmaceuticals Inc. common stock3 | E(RVRTX) | |
1 Unweighted average of bid yields on all outstanding fixed-coupon U.S. Treasury bonds neither due or callable in less than 10 years (risk-free rate of return proxy).
3 E(RVRTX) = RF + βVRTX [E(RM) – RF]
= + [ – ]
=